As foreshadowed in CSL’s release to the Australian Securities Exchange on 31 July, closing of the transaction will allow CSL to integrate the influenza vaccines division with its subsidiary, bioCSL. The combined business will create the second largest influenza vaccine business in the US$4 billion global industry and will have manufacturing plants in the US, UK, Germany and Australia, a commercial presence in approximately 20 countries, a differentiated product portfolio and strong pandemic and pre-pandemic franchises.
Download this release:
CSL completes Novartis influenza vaccine business acquisition (0.30Mb)
For further information, please contact:
|
Investors: |
Australia Media: |
|
US & Europe Media: |